Symbols

PACB

Pacific Biosciences·NASDAQ

--(--)

PACB fundamentals

PACB Q4 2025 Earnings

Pacific Biosciences (PACB) released its earnings on Feb 12, 2026: revenue was 44.65M (YoY +13.82%), beat estimates; EPS was -0.13 (YoY -1400.00%), beat estimates.

Revenue / YoY

44.65M

+13.82%

EPS / YoY

-0.13

-1400.00%

Report date

Feb 12, 2026

PACB Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 14% YoY to $44.6M, driven by record consumables (+15% YoY) and 42 Vega placements.
Clinical Momentum: Clinical/hospital consumables +55% YoY, EMEA revenue +45% YoY in Q4.
SPRQ-Nx Impact: 2026 launch of sub-$300 genome pricing, beta shows 25% higher throughput.
Gross Margin Expansion: 2025 non-GAAP gross margin 40% (vs. 33% in 2024), 2026 target 100-400 bps improvement.
Cash Flow Breakeven: 2026 focus on disciplined OpEx ($230M in 2025) and SPRQ-Nx gross margin expansion.

Earnings

EPS

Revenue

Revenue & Expenses

PACB has released its 2025 Q4 earnings report, with revenue of 44.65M, reflecting a YoY change of 13.82%, and net profit of -40.37M, showing a YoY change of -1802.70%. The Sankey diagram below clearly presents PACB's revenue sources and cost distribution.

Key Indicators

Pacific Biosciences (PACB) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Pacific Biosciences (PACB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Pacific Biosciences (PACB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Pacific Biosciences (PACB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown